Exocrine Pancreatic Insufficiency (EPI)
Oncology·MeSH: Exocrine Pancreatic Insufficiency
3 drugs in development·3 companies·1 clinical trial
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| pancreaze | VIVUS INC (VVUS) |
Phase 3(1)
| Drug | Company |
|---|---|
| sollpura | ANTHERA PHARMACEUTICALS INC (ANTH) |
Phase 2(1)
| Drug | Company |
|---|---|
| adrulipase | GridAI Technologies Corp. (GRDX) |
Compare drugs
Frequently asked questions
How many drugs are in development for Exocrine Pancreatic Insufficiency (EPI)?
BioSniper tracks 3 drugs in development for Exocrine Pancreatic Insufficiency (EPI) across 3 companies.
How many clinical trials target Exocrine Pancreatic Insufficiency (EPI)?
There are 1 clinical trial targeting Exocrine Pancreatic Insufficiency (EPI) tracked by BioSniper.
Deep-dive into Exocrine Pancreatic Insufficiency (EPI)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis